David Dellamonica: Focus on tangible actions to redefine cancer care ahead of ESMO 2024

David Dellamonica shared a post by Greg Rossi, Senior Vice President of Oncology Europe and Canada at AstraZeneca, on LinkedIn, adding the following:

“As we look ahead to ESMO 2024 later this week, it is vital that we don’t just focus on the incredible scientific advances we’re making, but also on the tangible actions and decisions needed to redefine cancer care and, one day, eliminate cancer as a cause of death. Check out Greg Rossi article below where he sets out some key areas of focus. What do you think?”

Quoting Greg Rossi’s post:

“Cancer continues to be one of the greatest health challenges facing Europe. While we have achieved significant scientific progress in recent decades, the reality remains: every second person will be diagnosed with cancer, and many will die from it.

We can’t accept this reality. But what will it take to redefine the future cancer care?

We need bold, tangible action. And we need to work together, with a focus on four key pillars of opportunity:

• Early detection
• Timely and equitable access to diagnostics and treatment
• Equitable access to clinical trials, and
• Sustainable and resilient health systems.

I’ve set out some thoughts in the following article – I encourage you to take a moment to read this and welcome all perspectives.”

Source: David Dellamonica/LinkedIn and Greg Rossi/LinkedIn

David Dellamonica is the Global Head of Precision Digital Healthcare at AstraZeneca. He leads the Precision Digital Health Delivery team, driving initiatives across all AstraZeneca business units and implementing digital solutions throughout the care pathway.

He has authored publications on AI, oncology, cardio-metabolic care pathways, and value-based partnerships. Dellamonica also actively contributes to discussions on the European Commission’s Data Strategy and AI White Paper.